15 Most Successful Penny Stocks in History
While most of us hear the words "the broader market" or use it in conversations and investing, usually refer only to a small part of the stock market.
Posts Tagged ‘Pharmacyclics Inc (PCYC)’
Pharmacyclics, Inc. (PCYC), Horizon Pharma PLC (HZNP), Auspex Pharmaceuticals Inc (ASPX): Hedge Fund’s Cashing In On Highest Q1 Gainers
The first quarter is up, and our data analytics show that the top three gainers for the quarter were all biotechnology or biopharmaceutical companies and included Pharmacyclics...
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY) Among Fund’s Other Top Picks
Julian Baker and Felix Baker's Baker Bros. Advisors’ top pick from the end of 2014 has paid off for the fund in a big way in 2015.
Mirati Therapeutics Inc. (MRTX): Baker Bros. Advisors Increases Stake in Growing Stock
Julian Baker and Felix Baker’s Baker Bros. Advisors recently disclosed an increase of around 929,700 shares to its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX).
Baker Bros Reveals New Stake in Aquinox Pharmaceuticals (AQXP)
In a new filing with the SEC, Julian Baker and Felix Baker’s Baker Bros. Advisors revealed new stake in Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).
Baker Bros. Advisors’ Latest Moves Involve ACADIA Pharmaceuticals Inc. (ACAD) & Synageva Biopharma Corp (TRMS)
Julian Baker and Felix Baker’s hedge fund, Baker Bros. Advisors, has recently tweaked its holdings in ACADIA Pharmaceuticals Inc.
Baker Bros. Advisors Reduces Exposure to MEI Pharma Inc (MEIP) to 3.4%
Julian and Felix Baker's Baker Bros. Advisors has decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares, from 1,130,317 shares revealed as held earlier.
Baker Bros. Strengthens Position in Seattle Genetics, Inc. (SGEN)
Julian Baker and Felix Baker have increased their exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) even higher.
Hedge Fund News: Bill Miller, Richard Perry & Alphonse Fletcher
Legg Mason’s Bill Miller is struggling to find the ‘extraordinary’ value in the US he did last year, and said equity markets could rise even higher in 2014.
Sanofi SA (ADR) (SNY), Roche Holding Ltd. (ADR) (RHHBY), GlaxoSmithKline plc (ADR) (GSK): Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?
There is perhaps nothing scarier than a cancer diagnosis.
Alexion Pharmaceuticals, Inc. (ALXN), Pharmacyclics, Inc. (PCYC), Aegerion Pharmaceuticals, Inc. (AEGR), Raptor Pharmaceutical Corp. (RPTP): Have These Four Biotechs Peaked?
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur.
Santarus, Inc. (SNTS), Pharmacyclics, Inc. (PCYC), Ariad Pharmaceuticals, Inc. (ARIA): Should You Jump on This Biotech After Profit-Taking?
After a truly remarkable 20-month 650% gain, shares of Santarus, Inc. (NASDAQ:SNTS) have fallen by more than 20% since its all-time high in early August.
Hedge Funds Are Dumping Dr. Reddy’s Laboratories Limited (ADR) (RDY)
To many of your fellow Dr.
Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?
In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to track Mr. Market.
Pharmacyclics, Inc. (PCYC), Johnson & Johnson (JNJ): The FDA Loves This Drug
It should come as no surprise to anyone that the Food and Drug Administration granted a priority review for Pharmacyclics, Inc.
Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): The Biggest Winners of the FDA’s Breakthrough Designation
Designed as a way to bring potentially life-changing drugs to pharmacy shelves faster than ever, the Food and Drug Administration Safety and Innovation Act, which passed last ...
Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
What Hedge Funds Think About Pharmacyclics, Inc. (PCYC)
In today’s marketplace, there are many metrics market participants can use to track publicly traded companies.
Allergan, Inc. (AGN): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the eyes of many of your fellow readers, hedge funds are seen as useless, old financial vehicles of an era lost to time.
Forest Laboratories, Inc. (FRX): Hedge Funds Aren’t Crazy About It, Insider Sentiment Unchanged
If you were to ask many investors, hedge funds are seen as delayed, old financial tools of an era lost to time.
Pharmacyclics, Inc. (PCYC), Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): This Small Company Is Winning the War Against Blood Cancer
About 15,680 Americans are diagnosed with chronic lymphocytic leukemia, or CLL, and approximately 5,000 new cases of mantle cell lymphoma, or MCL, occur in the U.S.
Regeneron Pharmaceuticals Inc (REGN), Pharmacyclics, Inc. (PCYC): Is There Pipeline Potential in These Biotech Stocks?
It is not uncommon for a biotechnology company to be valued solely on the potential of one drug.
Pharmacyclics, Inc. (PCYC), Annaly Capital Management, Inc. (NLY): Shorts Are Piling Into These Stocks. Should You Be Worried?
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Pharmacyclics, Inc. (PCYC) Set to Glide Higher
Pharmacyclics, Inc. (NASDAQ:PCYC) has been a good company to invest in, especially if you had bought shares back in 2009 when it traded around $1 per share.
What Does Celgene Corporation (CELG)’s Failed Trial Mean for Investors?
Early this morning, Celgene Corporation (NASDAQ:CELG) announced that it was discontinuing the phase 3 ORIGIN Trial evaluating Revlimid (lenalidomide) in B-Cell chronic lymphomatic...
Can Earnings Push Johnson & Johnson (JNJ) to New Heights?
Johnson & Johnson (NYSE:JNJ) is scheduled to release its quarterly earnings report tomorrow, and as a huge health-care conglomerate with a strong presence in consumer health-care...
Inovio Pharmaceuticals Inc (INO), Alnylam Pharmaceuticals, Inc. (ALNY): This Week in Biotech
With the SPDR S&P Biotech Index up 33% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Pharmacyclics, Inc. (PCYC): Will This Be the Breakthrough of All Breakthrough Therapy Drugs?
In July 2012, the Food and Drug Administration Safety and Innovation Act was signed into law; and little did we know at the time, but the drug development process was about to...
Pharmacyclics, Inc. (PCYC), Johnson & Johnson (JNJ) File for Marketing Approval for Ibrutinib
Pharmacyclics, Inc. (NASDAQ:PCYC) and development partner Janssen, a division of Johnson & Johnson (NYSE:JNJ), announced on Wednesday that a New Drug Application, or NDA, has...
Why Pharmacyclics, Inc. (PCYC) Shares Vaulted Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Onyx Pharmaceuticals, Inc. (ONXX), Pharmacyclics, Inc. (PCYC): Will This Biotech Acquisition Buzz Lead to More Buyouts?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is trading higher after rejecting a takeover bid.
Amgen, Inc. (AMGN) Stirs the Pot in the Cancer-Related Sector
Several companies are fighting to be the first to release a treatment or cure for cancer that is a game-changer, and this battle has created a field where firms are looking to...
ACADIA Pharmaceuticals Inc. (ACAD): Look Before You Leap With This Company
ACADIA Pharmaceuticals Inc.
Oncolytics Biotech, Inc. (USA) (ONCY): This High-Risk, High-Reward Biotech Is Worth a Look
Let me preface this by saying that investing in the biotech sector can sometimes be nothing more than speculating.
ACADIA Pharmaceuticals Inc. (ACAD) Soars On Hedge Fund Investment
One of the best ways that retail investors can try to decide which stocks will make for a promising investment is to look at what the hedge funds are doing.
Apple Inc. (AAPL), Alcatel Lucent SA (ADR) (ALU): 4 Stocks On The Verge Of Breaking Out!
Rite Aid Corporation (NYSE:RAD) has been my favorite stock for the better part of the last year.
Bristol Myers Squibb Co. (BMY), Pharmacyclics, Inc. (PCYC): Hedging Against Leukemia
As I noted 11 weeks ago, cancer statistics are both staggering and disappointing.
Corning Incorporated (GLW), Pharmacyclics, Inc. (PCYC), 3D Systems Corporation (DDD): How To Play Them
An analyst upgrade can sometimes be highly useful in allowing you to learn about a new company that might have flown under-the-radar.
Sarepta Therapeutics Inc (SRPT), Pharmacyclics, Inc. (PCYC): Are These Billion-Dollar Biotechs Overvalued?
Biotechs with market caps of a billion dollars or more are a dime a dozen. Well, actually, they're more like $12 billion or more a dozen, but you get the point.
Biogen Idec Inc. (BIIB), Pharmacyclics, Inc. (PCYC), Immunomedics, Inc. (IMMU), and Tackling Cancer, Non-Hodgkin Lymphoma’s Biggest Current & Upcoming Players
As I noted seven weeks ago, cancer statistics are both staggering and disappointing.
Pharmacyclics, Inc. (PCYC), Keryx Biopharmaceuticals (KERX): These Cutting-Edge Science Stocks Are Soaring
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Pfizer Inc. (PFE) & More…a ‘Breakthrough’ May Be on the Way for Breast Cancer Patients
The process of developing a drug from start to finish is incredibly arduous, usually involves around $1 billion in costs, and can take upwards of a decade to complete.
Johnson & Johnson (JNJ), And Why The FDA’s Latest Designation is More Bling Than Bite
Johnson & Johnson (NYSE:JNJ) announced on Monday that it had received a third Breakthrough Therapy Designation for the blood cancer drug ibrutinib that it's developing with Pharmacyclics...
3 Humongous Health-Care Stocks This Week: Infinity Pharmaceuticals Inc. (INFI)
There's power in positive thinking. The late author Norman Vincent Peale made plenty of money off that philosophy.
Wildly Growing Stocks, With a Hefty Dividend, Too: 3D Systems Corporation (DDD) and More
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Whoa! These 3 Stocks Are on the Ball: Pharmacyclics, Inc. (PCYC)
With the president calling for new initiatives on the federal minimum wage, immigration, gun control, and early childhood education, the Dow Jones Industrial Average was filled...
Gilead Sciences, Inc. (GILD): A Pharmaceutical Growth Story You Can’t Afford To Miss
Gilead Sciences, Inc. (NASDAQ:GILD) is the world’s largest maker of HIV drugs, but has taken on a number of new initiatives to enter other areas of treatment.
The FDA Made Biotech Investing Harder (But More Lucrative): Johnson & Johnson (JNJ)
For instance, it's hard to make money on shoo-in Food and Drug Administration approvals. The approval is already reflected in the price.
This Week in Biotech: AbbVie Inc (ABBV) and More
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
